Table 2.
Main results of studies assessing the effect of anti-TNF treatment on markers of bone turnover in RA
| Author | Year | Drug | Patients (n) | RANKL | OPG | RANKL/OPG | OC | PINP | CTX | NTX | DPD | BAP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ziolkowska | 2002 | INF | 21 | ↓ | ↓ | ↔ | – | – | – | – | – | – |
| Vis | 2003 | INF | 68 | – | – | – | ↑ | ↑ | – | – | – | ↔ |
| Lange | 2005 | INF | 26 | – | – | – | ↑ | – | – | – | – | – |
| Seriolo | 2006 | INF/ETA | 9/11 | – | – | – | ↑ | – | – | – | ↓ | – |
| Torikai | 2006 | INF | 17 | – | – | – | – | – | – | ↓ | ↓ | ↔ |
| Vis | 2006 | INF | 102 | ↓ | ↔ | ↓ | ↔ | – | ↓ | – | – | – |
| Marotte | 2007 | INF | 90 | – | – | – | ↔ | – | ↔ | – | – | – |
| Chopin | 2008 | INF | 48 | – | – | – | – | ↔ | ↔ | – | – | – |
| Yasunori | 2008 | ETA | 30 | ↓ | ↔ | ↓ | – | – | – | – | ↓ | – |
| Dischereit | 2013 | INF | 18 | – | – | – | ↑ | – | – | – | – | – |
| Korczowska | 2013 | INF | 36 | – | – | – | ↓ | – | – | ↓ | ↓ | – |
| Szentpetery | 2013 | INF/ETA/ADA | 35 | – | – | – | ↔ | ↔ | ↓ | – | ↓ | ↑ |
| Lim | 2014 | ETA | 33 | – | – | ↔ | – | ↔ | ↑ | – | – | ↔ |
| Okano | 2013 | INF/ETA | 90/27 | – | – | – | – | – | – | ↓ | – | ↔ |
ADA, Adalimumab; BAP, bone alkaline phosphatase; CTX, C- telopeptide of type I collagen; DPD, deoxypyridinoline; ETA, etanercept; INF, infliximab; NTX, N- telopeptide of type I collagen; OC, osteocalcin; OPG, osteoprotegerin; PINP, N-terminal propeptide of type I collagen; RANKL, receptor activator of the NFkappaB ligand.